BTK and Sjogren syndrome: Likewise, no significant increase in severe bleeding was observed to the highly selective novel Btk inhibitor remibrutinib,29 currently undergoing clinical studies for chronic spontaneous urticaria ([NCT03926611]30 and Sjögren's syndrome [NCT04035668]), which also showed high selectivity for Btk in kinase screens.31